CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 50 enrolled
Drug / intervention
intravenous immunoglobulins (IVIG) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00176059
NCT00176059Early Ph 1Completed
CompareCT.gov

Immunoglobulin Induction Therapy in Renal Transplant Recipients on Tacrolimus/Azathioprine or Tacrolimus/MMF: Effects on Th1, Th2, B Cell-/Monokine Responses and Immunoregulatory Autoantibody Levels

University of Giessen·interventional·Posted Sep 15, 2005·Updated May 10, 2007

In Brief

A Early Phase 1 clinical trial evaluating intravenous immunoglobulins (IVIG) and kidney transplantation for Renal Failure, Chronic and Renal Transplantation. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The aim of this randomized prospective study in renal transplant recipients is to investigate immunological short and long-term effects of an IVIG induction therapy. Furthermore clinical endpoints (patient and graft survival, incidence of acute and chronic rejection, infectious diseases and graft function) up to three years posttransplant will be analyzed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Failure, Chronic, Renal Transplantation
CountriesGermany
CollaboratorsHeidelberg University, Astellas Pharma Inc, Hoffmann-La Roche, Aventis Pharmaceuticals

Timeline

Early Ph 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2005
Enrollment StartOct 1, 2001
Study CompletionMay 1, 2006
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

intravenous immunoglobulins (IVIG)drug

kidney transplantationprocedure